Biosimilars and Follow-On Biologics 2014 Americas
Fiona Greer, SGS Global Director, BioPharma Services Development, will be giving a presentation on Mass Spectrometry Analysis for Biosimilars at the Biosimilars and Follow on Biologics 2104 Americas conference in Philadelphia
February 10, 2014
February 12, 2014
Philadelphia, United States
This conference examines a number of challenges including commercial, regulatory, and technical, all of them in turn and discusses for example: the current commercial trends of biosimilars; what the commercial impact of them is; and what is happening in the BRIC countries.
The conference also looks at the latest global regulatory guidelines and issues surrounding biosimilars and what this means for the data exclusivity, is there a need for a balance between innovation and competition?
Technical issues with biosimilars however are the major concern. Biological drugs unlike the more common small-molecule drugs maybe more sensitive to changes in manufacturing process due to its high molecular complexity, so biosimilar producers have to prove that the overall effects are the same.
Following the success of the first generation Monoclonal antibodies blockbusters, here we analyze many challenges to be faced to bring more efficient and affordable anti-body based drugs to the market.
Finally, biobetters are a new category of drug: why just copy a drug when you can improve it? This workshop examines the potential of biobetters for companies and how to maximize opportunities.
SGS's Fiona Greer, Global Director, BioPharma Services Development, will be presenting on Mass Spectrometry Analysis for Biosimilars - Why mass spectrometry (MS) is growing in importance as comparator.